What is the HIV state of the art?

Learn about the “State of the Art” in HIV care from three of the biggest names in the business on Thursday, Oct. 5, at IDWeek 2017 in San Diego.

Joseph Eron Jr., MD, director of the UNC Center for AIDS Research Medicine at the University of North Carolina at Chapel Hill, in his talk “What to Start and When to Switch,” will help clinicians identify the most appropriate antiretroviral therapy regimens for initial HIV treatment in adults, as well as subsequent therapies for management of infection. Much of Dr. Eron’s research has focused on HIV resistance to antiretroviral therapy and the use of resistance testing and pharmacokinetic assessment to construct successful therapy.

Speaking about cost considerations in HIV treatment is Rochelle Walensky, MD, MPH, of the division of infectious diseases, Massachusetts General Hospital. Dr. Walensky will help attendees better understand and evaluate drug costs and their potential impact on HIV treatment. Dr. Walensky has published work on the impact of routine HIV screening, on the clinical and cost-effectiveness of HIV vaccines of varying efficacies, and on the value of primary genotypic resistance testing.

Finally, Gregory Lucas, MD, PhD, of Johns Hopkins University, Baltimore, will review the approaches to effectively responding to the substance and mental health needs of patients with HIV in his talk “Substance Use and HIV: Vicious Twins.” Dr. Lucas has recently published on the relationship between injection drug networks, HIV risk behavior, and the lack of viral suppression.

Moderators will be Eric Daar, MD, of Harbor-UCLA Medical Center, and Monica Gandhi, MD, MPH, of the University of California, San Francisco.

The symposium will take place Thursday, Oct. 5, from 8:30 a.m. to 10:00 a.m. in Room 06CF at the San Diego Convention Center.

rpizzi@frontlinemedcom.com

On Twitter @richpizzi

Learn about the “State of the Art” in HIV care from three of the biggest names in the business on Thursday, Oct. 5, at IDWeek 2017 in San Diego.

Joseph Eron Jr., MD, director of the UNC Center for AIDS Research Medicine at the University of North Carolina at Chapel Hill, in his talk “What to Start and When to Switch,” will help clinicians identify the most appropriate antiretroviral therapy regimens for initial HIV treatment in adults, as well as subsequent therapies for management of infection. Much of Dr. Eron’s research has focused on HIV resistance to antiretroviral therapy and the use of resistance testing and pharmacokinetic assessment to construct successful therapy.

Speaking about cost considerations in HIV treatment is Rochelle Walensky, MD, MPH, of the division of infectious diseases, Massachusetts General Hospital. Dr. Walensky will help attendees better understand and evaluate drug costs and their potential impact on HIV treatment. Dr. Walensky has published work on the impact of routine HIV screening, on the clinical and cost-effectiveness of HIV vaccines of varying efficacies, and on the value of primary genotypic resistance testing.

Finally, Gregory Lucas, MD, PhD, of Johns Hopkins University, Baltimore, will review the approaches to effectively responding to the substance and mental health needs of patients with HIV in his talk “Substance Use and HIV: Vicious Twins.” Dr. Lucas has recently published on the relationship between injection drug networks, HIV risk behavior, and the lack of viral suppression.

Moderators will be Eric Daar, MD, of Harbor-UCLA Medical Center, and Monica Gandhi, MD, MPH, of the University of California, San Francisco.

The symposium will take place Thursday, Oct. 5, from 8:30 a.m. to 10:00 a.m. in Room 06CF at the San Diego Convention Center.

rpizzi@frontlinemedcom.com

On Twitter @richpizzi

Learn about the “State of the Art” in HIV care from three of the biggest names in the business on Thursday, Oct. 5, at IDWeek 2017 in San Diego.

Joseph Eron Jr., MD, director of the UNC Center for AIDS Research Medicine at the University of North Carolina at Chapel Hill, in his talk “What to Start and When to Switch,” will help clinicians identify the most appropriate antiretroviral therapy regimens for initial HIV treatment in adults, as well as subsequent therapies for management of infection. Much of Dr. Eron’s research has focused on HIV resistance to antiretroviral therapy and the use of resistance testing and pharmacokinetic assessment to construct successful therapy.

Speaking about cost considerations in HIV treatment is Rochelle Walensky, MD, MPH, of the division of infectious diseases, Massachusetts General Hospital. Dr. Walensky will help attendees better understand and evaluate drug costs and their potential impact on HIV treatment. Dr. Walensky has published work on the impact of routine HIV screening, on the clinical and cost-effectiveness of HIV vaccines of varying efficacies, and on the value of primary genotypic resistance testing.

Finally, Gregory Lucas, MD, PhD, of Johns Hopkins University, Baltimore, will review the approaches to effectively responding to the substance and mental health needs of patients with HIV in his talk “Substance Use and HIV: Vicious Twins.” Dr. Lucas has recently published on the relationship between injection drug networks, HIV risk behavior, and the lack of viral suppression.

Moderators will be Eric Daar, MD, of Harbor-UCLA Medical Center, and Monica Gandhi, MD, MPH, of the University of California, San Francisco.

The symposium will take place Thursday, Oct. 5, from 8:30 a.m. to 10:00 a.m. in Room 06CF at the San Diego Convention Center.

rpizzi@frontlinemedcom.com

On Twitter @richpizzi